Management of Adolescent Depression

Initial Assessment and Treatment Approach

Depression management should be customized based on severity, suicide risk, and presence of comorbid conditions, according to the American Academy of Pediatrics 1
A "common factors" approach focusing on therapeutic alliance and shared decision-making should be incorporated into all treatment plans, as recommended by the American Academy of Pediatrics 2
Common sense approaches including physical exercise, sleep hygiene, and adequate nutrition should be included in management, as suggested by the American Academy of Pediatrics 1

The American Academy of Pediatrics recommends that fluoxetine is the only FDA-approved antidepressant for children and adolescents with depression 1
The effective dose of fluoxetine is typically 20 mg daily, with a maximum dose of 60 mg daily, as recommended by the American Academy of Pediatrics 3
CBT alone has shown limited efficacy with only 43.2% response rate compared to combined treatment, according to the American College of Physicians 4

Fluoxetine should be started at 10 mg daily and increased by 10-20 mg increments at no less than weekly intervals, as recommended by the American Academy of Pediatrics 3
Escitalopram is FDA-approved for adolescents aged 12 years and older, according to the American Academy of Pediatrics 1
Sertraline may be considered, with a starting dose of 25 mg, effective dose of 50 mg, and maximum dose of 200 mg, as suggested by the American Academy of Pediatrics 3

Patients should be assessed in person within 1 week of treatment initiation and regularly thereafter, with evaluation of ongoing depressive symptoms, suicide risk, possible adverse effects, treatment adherence, and new or ongoing environmental stressors, as recommended by the American Academy of Pediatrics 3

The World Health Organization recommends that fluoxetine may be considered for adolescents with depression in non-specialist settings, with close monitoring for suicidal ideation/behavior 5
Higher starting doses of SSRIs are associated with increased risk of deliberate self-harm, according to the American Academy of Pediatrics 3
All SSRIs should be slowly tapered when discontinued to prevent withdrawal effects, as recommended by the American Academy of Pediatrics 3

Collaborative care models that include parent involvement, choice of treatment type, and regular follow-up have shown significant improvements in depression outcomes at 6 and 12 months, according to the American College of Physicians 4
Medication maintenance should be considered for at least 6-12 months after response, as the greatest risk of relapse occurs in the first 8-12 weeks after discontinuation, as recommended by the American Academy of Pediatrics 3

For adolescents with mild depression, consider a period of active support and monitoring (6-8 weeks) before initiating formal treatment, as recommended by the American Academy of Pediatrics 6, 7

Cognitive-behavioral therapy (CBT) and interpersonal psychotherapy for adolescents (IPT-A) have demonstrated effectiveness in reducing depression severity, with IPT-A showing significant effects on reducing depression severity, suicidal ideation, and hopelessness compared to treatment as usual 6
Adolescents with higher baseline interpersonal difficulties show greater and more rapid symptom reduction with IPT-A 6

Reassess diagnosis and treatment if no improvement occurs after 6-8 weeks, as suggested by the American Academy of Pediatrics 7
If no improvement after 6-8 weeks despite adequate treatment, explore poor adherence, comorbid disorders, or ongoing conflicts/abuse before changing the treatment plan, according to the American Academy of Pediatrics 7

Immediately consult for moderate or severe depression with complicating factors, such as coexisting substance abuse, psychosis, or active suicidality, as recommended by the American Academy of Pediatrics 6
For partial response to maximum tolerated SSRI dosage, add evidence-based psychotherapy if not already initiated, as suggested by the American Academy of Pediatrics 7
Do not conclude treatment is ineffective before completing an adequate trial: 8 weeks at optimal dosage for antidepressants, as stated by the Journal of the American Academy of Child and Adolescent Psychiatry 8
Failing to address comorbid conditions, poor adherence, or ongoing environmental stressors will undermine treatment response, according to the American Academy of Pediatrics 7

CBT demonstrated a 43.2% response rate versus 34.8% for placebo in controlled trials, though this represents modest efficacy when used as monotherapy, as reported by the Annals of Internal Medicine 9
Combined fluoxetine plus CBT achieved a 71% response rate versus 35% for placebo, significantly superior to either treatment alone, according to the Annals of Internal Medicine 9
Escitalopram showed superiority to placebo in improving depression symptoms in adolescents, as noted in the Annals of Internal Medicine 9

The FDA black box warning emphasizes increased risk of suicidal thinking and behavior in children and adolescents during early antidepressant treatment, though no completed suicides were reported in controlled trials, as stated in the Annals of Internal Medicine 9 and 10

Collaborative care interventions that include parent involvement, choice of treatment type, and regular follow-up with depression care managers showed superior outcomes compared to usual care, with greater reductions in depressive symptoms at 6 and 12 months, as reported in the Annals of Internal Medicine 9 and 10
Response rates at 12 months were significantly higher with collaborative care, as were remission rates at 6 months and 12 months, according to the Annals of Internal Medicine 9 and 10